abstracts Annals of Oncology

AstraZeneca; Advisory/Consultancy, Steering committee: Tesaro. D. Lorusso: Advisory/Consultancy: 822P Comparison of toxicities of PARP inhibitors used in gynaecological
Clovis Oncology; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: ImmunoGen; Advisory/ cancers observed at a large cancer centre
Consultancy: Merck; Advisory/Consultancy, Travel/Accommodation/Expenses: PharmaMar; Advi-
sory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Takeda; Advi-
sory/Consultancy: Tesaro. C. Aghajanian: Advisory/Consultancy, Research grant/Funding (self):
B. Nagy1, R.D. Morgan1, G.C. Jayson1, C. Mitchell1, A.R. Clamp1, J.H. Hasan2
AbbVie; Advisory/Consultancy, Research grant/Funding (self): Genentech; Advisory/Consultancy, 1
Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK;
Research grant/Funding (self): Clovis Oncology; Advisory/Consultancy: Eisai/Merck; Advisory/Con- 2
sultancy: ImmunoGen; Advisory/Consultancy: Mersana Therapeutics; Advisory/Consultancy: Roche; General Medicine, The Christie NHS Foundation Trust, Manchester, UK
Advisory/Consultancy: Tesaro; Research grant/Funding (self): AstraZeneca. A. Oaknin: Advisory/
Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Clovis Background: Olaparib (O) was first poly ADP-ribose polymerase inhibitor (PARPi)
Oncology; Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consul- approved for use in the UK as maintenance therapy in relapsed BRCA mutated ovarian
tancy: Genmab/Seattle Genetics; Advisory/Consultancy, Research grant/Funding (institution): cancer in 2017. Since then Niraparib (N) and Rucaparib (R) have also been approved
ImmunoGen; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/
Expenses: PharmaMar; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accom-
as maintenance therapy in patients with relapsed ovarian cancer with and without
modation/Expenses: Roche; Advisory/Consultancy, Research grant/Funding (institution): Tesaro; BRCA gene mutations. Though clinicians now have three drugs to choose from, a lack
Research grant/Funding (institution): AbbVie Deutschland; Research grant/Funding (institution): of head-to-head data means the choice is not a straight forward one. We aim to
Ability Pharmaceuticals; Research grant/Funding (institution): Advaxis; Research grant/Funding compare toxicities of the PARPi drugs in order to give clinicians a better idea of which
(institution): Aeterna Zentaris; Research grant/Funding (institution): Amgen; Research grant/Funding drugs to use in certain scenarios. We report the real world experience of the three
(institution): Aprea Therapeutics; Research grant/Funding (institution): Eisai; Research grant/Funding PARPi at a UK cancer centre.
(institution): Merck/Merck Sharp & Dohme; Research grant/Funding (institution): Millennium
Pharmaceuticals. N. Colombo: Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy: Methods: Retrospective data was collected from every patient with a gynaecological
Advaxis; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Biocad; Advisory/Consultancy: cancer who had a PARPi up to the 19th of March 2020. Data lock was the 10th of May
GlaxoSmithKline; Advisory/Consultancy: Merck Sharp & Dohme; Advisory/Consultancy: Pfizer; 2020.
Advisory/Consultancy: PharmaMar; Advisory/Consultancy: Roche; Advisory/Consultancy: Takeda;
Advisory/Consultancy: Tesaro. J. Weberpals: Research grant/Funding (self): AbbVie; Advisory/Con- Results: 119 patients with relapsed platinum-sensitive ovarian/fallopian tube or pri-
sultancy, Research grant/Funding (self): AstraZeneca. A.R. Clamp: Advisory/Consultancy, Research mary peritoneal cancer were included. The group contained 72 patients with BRCA
grant/Funding (self), Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy, Travel/ wild-type (wtBRCA), 46 patients with germline mutated BRCA (gBRCA) and one pa-
Accommodation/Expenses: GlaxoSmithKline; Advisory/Consultancy: Roche; Travel/Accommodation/ tient with an unknown BRCA status. 71 patients received N, 37 received O and12
Expenses: Clovis Oncology. G. Scambia: Advisory/Consultancy: Clovis Oncology; Advisory/Consul-
tancy: AstraZeneca; Advisory/Consultancy: PharmaMar; Advisory/Consultancy: Roche; Advisory/
patients received R. gBRCA patients were more likely to receive O. wtBRCA patients
Consultancy: Tesaro. A. Leary: Advisory/Consultancy, Research grant/Funding (institution), Travel/ were more likely to receive N or R. The median number of cycles was 5. The pre-
Accommodation/Expenses: Clovis Oncology; Advisory/Consultancy, Research grant/Funding (insti- liminary median PFS for the gBRACA population is 14.9 months. The preliminary
tution): Ability Pharmaceuticals; Advisory/Consultancy, Research grant/Funding (institution), Travel/ median PFS for the wtBRACA population is 7.2 months. Treatment interruption, dose
Accommodation/Expenses: AstraZeneca; Advisory/Consultancy: Biocad; Advisory/Consultancy: reduction and early stoppage all favoured O. The incidence of grade
3 cytopenia was
GamaMabs; Advisory/Consultancy: Genmab/Seattle Genetics; Advisory/Consultancy: Gritstone; similar across the three drugs. Derangement of liver function, abdominal pain,
Advisory/Consultancy: GlaxoSmithKline; Advisory/Consultancy: Merck Serono; Advisory/Consultancy, nausea, vomiting and diarrhoea was observed more often with R. Hypertension,
Research grant/Funding (institution): Merck Sharp & Dohme; Advisory/Consultancy, Research grant/
Funding (institution): Tesaro; Research grant/Funding (institution): Agenus; Research grant/Funding
insomnia, mucositis and dyspnoea were seen with more often with N. Evaluation of
(institution): Incyte; Research grant/Funding (institution): Inivata; Research grant/Funding (institu- correlation between BRCA status and incidence of adverse events is ongoing. 41
tion): Iovance; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution), patients have thus far completed chemotherapy post progression on PARPi. The
Travel/Accommodation/Expenses: Roche; Research grant/Funding (institution): Sanofi. R.W. Hollo- myelosupressive effects of chemotherapy post-PARPi and its correlations with the
way: Advisory/Consultancy, Speaker Bureau/Expert testimony: Clovis Oncology; Advisory/Consul- individual drugs and BRCA status is being evaluated. Mature data will be presented at
tancy, Speaker Bureau/Expert testimony: AstraZeneca; Speaker Bureau/Expert testimony: Tesaro. M. the meeting.
Amenedo Gancedo: Speaker Bureau/Expert testimony: Clovis Oncology; Speaker Bureau/Expert
testimony: AstraZeneca; Speaker Bureau/Expert testimony: PharmaMar; Speaker Bureau/Expert Conclusions: Efficacy of PARPi was superior in the gBRCA population compared to
testimony: Roche. P.C. Fong: Advisory/Consultancy: Clovis Oncology; Honoraria (self), Advisory/ wtBRCA. O was the least toxic PARPi.
Consultancy: AstraZeneca. J.C. Goh: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert
testimony, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Legal entity responsible for the study: The authors.
Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy: Tesaro; Speaker
Bureau/Expert testimony: Ipsen; Speaker Bureau/Expert testimony: Merck Sharp & Dohme; Travel/
Funding: Has not received any funding.
Accommodation/Expenses: Astellas. D.M. O’Malley: Advisory/Consultancy, Research grant/Funding Disclosure: All authors have declared no conflicts of interest.
(institution): Clovis Oncology; Advisory/Consultancy, Research grant/Funding (institution): AbbVie;
Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, https://doi.org/10.1016/j.annonc.2020.08.961
Research grant/Funding (institution): Eisai; Advisory/Consultancy: Genentech/Roche; Advisory/
Consultancy: Genelux; Advisory/Consultancy, Research grant/Funding (institution): Iovance Bio-
therapeutics; Advisory/Consultancy: Janssen; Advisory/Consultancy, Research grant/Funding (insti-
tution): Novocure; Advisory/Consultancy: Regeneron; Advisory/Consultancy, Research grant/Funding
(institution): Tesaro; Advisory/Consultancy, Research grant/Funding (institution): Agenus; Advisory/ 823P Extended follow-up of a real-world cohort of patients (pts) with
Consultancy, Research grant/Funding (institution): Amgen; Advisory/Consultancy: Ambry; Advisory/ BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC)
Consultancy, Research grant/Funding (institution): Gynecologic Oncology Group Foundation; receiving olaparib maintenance therapy: The GINECO RETROLA
Speaker Bureau/Expert testimony: National Comprehensive Cancer Network; Research grant/ study
Funding (institution): Ajinomoto; Research grant/Funding (institution): Array BioPharma; Research
grant/Funding (institution): Bristol-Myers Squibb; Research grant/Funding (institution): Cerulean
Pharma; Research grant/Funding (institution): EMD Serono; Research grant/Funding (institution):
T. de La Motte Rouge1, L. Bengrine Lefevre2, M-A. Mouret-Reynier3, B. Asselain4,
ERGOMED Clinical Research; Research grant/Funding (institution): Genentech; Research grant/ B. Lucas5, C. Gavoille6, C. Cornila7, D. Spaeth8, E. Colomba9, A. Patsouris10,
Funding (institution): INC Research; Research grant/Funding (institution): inVentiv Health Clinical; M. Fabbro11, C. Chakiba12, P. Toussaint13, H. Simon14, D. Berton15, D. Garbay16,
Research grant/Funding (institution): Janssen Research and Development; Research grant/Funding C. Garnier Tixidre17, D. Coeffic18, O. Collard19, C. Lefeuvre-Plesse1
(institution): Ludwig Institute for Cancer Research; Research grant/Funding (institution): New Mexico
1
Cancer Care Alliance; Research grant/Funding (institution): PRA International; Research grant/ Medical Oncology, Eugene Marquis Cancer Center, Rennes, France; 2Medical
Funding (institution): Regeneron Pharmaceuticals; Research grant/Funding (institution): Serono; Oncology, Centre Georges Francois Leclerc, Dijon, France; 3Medical Oncology, Centre
Research grant/Funding (institution): Stemcentrx; Research grant/Funding (institution): Tracon Jean Perrin, Clermont Ferrand, France; 4Biostatistics, ARCAGY-GINECO, Paris, France;
5
Pharmaceuticals; Research grant/Funding (institution): VentiRx; Research grant/Funding (institu- Oncologie, Clinique Pasteur-CFRO, Brest, France; 6Medical Oncology, Institut de
tion): Yale University. T. Cameron, L. Maloney, S. Goble: Shareholder/Stockholder/Stock options, Full/
Cancérologie de Lorraine, Vandoeuvre Les Nancy, France; 7Medical Oncology, Centre
Part-time employment: Clovis Oncology. R.L. Coleman: Advisory/Consultancy, Research grant/
Funding (self): Clovis Oncology; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Hospitalier Régional d’Orléans, Orléans, France; 8Medical Oncology, Centre d’Onco-
Research grant/Funding (self): Gateway Foundation; Advisory/Consultancy, Research grant/Funding logie de Gentilly, Nancy, France; 9Cancer Medicine Department, Gustave Roussy
(self): Janssen; Research grant/Funding (self): Judy Reis/Albert Pisani, MD, Ovarian Cancer Research Cancer Campus, Paris-Saclay University, Villejuif, France; 10Medical Oncology
Fund; Research grant/Funding (self): Merck; Research grant/Funding (self): National Institutes of Department, ICO Pays de Loire, Angers, France; 11Medical Oncology, ICM Regional
Health; Advisory/Consultancy, Research grant/Funding (self): Roche/Genentech; Research grant/ Cancer Institute of Montpellier, Montpellier, France; 12Medical Oncology, Institut
Funding (self): V-Foundation; Advisory/Consultancy: Agenus; Advisory/Consultancy: GamaMabs; Bergonié, Bordeaux, France; 13Département d’Oncologie Medicale, Centre Léon
Advisory/Consultancy: Genmab; Advisory/Consultancy: OncoQuest; Advisory/Consultancy: Pfizer
Bérard, Lyon, France; 14Medical Oncology, Hôpital Morvan - Centre Hospitalier Uni-
(Medivation); Advisory/Consultancy: Regeneron; Advisory/Consultancy: Tesaro; Officer/Board of
Directors, Endowment: Ann Rife Cox Chair in Gynecology. J.A. Ledermann: Honoraria (self), Advisory/ versitaire, Brest, France; 15Medical Oncology, Institut de Cancérologie de l’Ouest ( ICO)
Consultancy: Clovis Oncology; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): René Gauducheau, Saint-Herblain, France; 16Medical Oncology, Clinique Tivoli Ducos,
AstraZeneca; Honoraria (self), Advisory/Consultancy: Pfizer; Advisory/Consultancy: Artios Pharma; Bordeaux, France; 17Medical Oncology, Groupe Hospitalier Mutualiste de Grenoble,
Advisory/Consultancy: Cristal Therapeutics; Advisory/Consultancy, Research grant/Funding (self): Grenoble, France; 18Medical Oncology, Institut du Cancer Courlancy, Reims, France;
Merck/Merck Sharp & Dohme; Advisory/Consultancy: Regeneron; Advisory/Consultancy: Roche; 19
Medical Oncology, Institut de Cancérologie de la Loire -Lucien Neuwirth ICLN, Saint-
Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy: Tesaro. Priest-en-Jarez, France
https://doi.org/10.1016/j.annonc.2020.08.960
Background: Olaparib was initially approved by the European Medicines Agency
(EMA) as maintenance treatment for pts with BRCAm platinum-sensitive relapsed
high-grade EOC, following the results of a randomized phase II trial (study 19). The
RETROLA study aimed to evaluate whether the outcome observed in this clinical trial
are reflected in routine clinical practice, in a real-world cohort of pts.
Methods: We planned to include 130 pts in this retrospective cohort. French centers
(n¼28) representative of French regions and of mode of practice were asked to

Volume 31 - Issue S4 - 2020 S621

Annals of Oncology abstracts

participate. Overall, 251 pts were identified. At each center, up to 6 pts who started between PARPi and Pt cast doubts on the benefit from ssq Pt after PARPi progression.
olaparib (400 mg bid, capsule formulation) between 03/2014 and 03/2017 were We provide RWD on this issue.
randomly selected and included. Medical records were reviewed for clinic and
Methods: We included HGSOC p treated with ssq CT after progression to mainte-
pathologic characteristics, survival outcomes and safety. Our primary objective was to
nance PARPi until 31st Dec 2019 in 3 large hospitals. Endpoints were overall response
assess efficacy of olaparib in real-world pts treated upon initial EMA label (ptsEMA) by
rate (ORR), median (m) PFS and overall survival (mOS) to ssq Pt after PARPi. Analysis
evaluating progression free survival (PFS) from olaparib initiation.
were also performed according to 3 populations: p who received ssq non-Pt CT, p with
Results: Overall, 128 pts were included in the analysis and 89 were treated according Pt-free interval (PFI) 6-12 months (mo) and p with PFI >12 mo.
to EMA label. Main reasons to be given olaparib off-label were absence of radiological
Results: 54 p were identified (57.4 % BRCAmut). 4p (7.4%) received PARPi after 1st
response following platinum-based chemotherapy (n¼22) and non high-grade serous
line CT, 25 (46.3%) after 2nd line, and 25 (46.3%) after
3rd line. 34p (63%) received
EOC subtype (n¼14). BRCA1/2 mutation was present in 126 pts (98%). Most pts (68%)
olaparib and 20 (37%) niraparib. mPFS of PARPi as maintenance in the recurrent
received olaparib after 3 or more lines of platinum-based chemotherapy. Median
setting was 7.5 mo and PFS2 15.4 mo. Distribution of ssq CT schemes and their best
follow up was 41.8 months. Median PFS in ptsEMA was 17.0 months (95% CI: 14.7-
responses are shown in the table. ORR to ssq Pt was 33.3%, and progression disease
21.3). Median PFS and overall survival (OS) in the whole population were 15.5 months
(PD) 28.6%. ORR in p who received ssq Pt-free CT, p with PFI 6-12 mo, and p with PFI
(95% CI: 12.6-18.1) and 33.6 months (95% CI: 28.7; 40.3), respectively. Fourteen
>12 mo were 28.6%, 22.7% and 45%, respectively. The 4 identified complete re-
(11.2%) pts stopped olaparib for toxicity reason and 75 (58.6%) had at least one dose
sponses (CR) occurred among BRCAmut p receiving PARPi in the recurrent setting and
reduction or one dose interruption. Related myelodysplastic syndrome and second
PFI>12. Survival endpoints of ssq CT are shown in the table. mPFS and mOS were
cancers were diagnosed in respectively n¼5 and n¼1 pts. Number of previous lines of
significantly longer in the PFI >12 subgroup versus the others. Survival did not change
systemic therapy 2 was associated with prolonged PFS.
when excluding the 4p who received PARPi as 1st line (Table).
Conclusions: With an extended follow-up, efficacy and toxicity of olaparib in real-
world cohort of pts are consistent with findings observed in study 19 and SOLO-2
trials. Table: 824P

Clinical trial identification: NCT04152941. Non Pt-CT Pt-CT p

Legal entity responsible for the study: ARCAGY-GINECO. N[9
PFI 6-12 mo N¼24 PFI >12 mo N¼21
Funding: AstraZeneca.
BRCAmut (n, %) 5 (55.6) 12 (50) 14 (66.7) 0.055
Disclosure: T. de La Motte Rouge: Advisory/Consultancy, Travel/Accommodation/Expenses: From ssq CT after PARPi:
AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses: Clovis Oncology; Advisory/
Consultancy, Travel/Accommodation/Expenses: Tesaro GSK; Advisory/Consultancy, Research grant/
Best responses (n, %)* 0.010
Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Ac- CR 0 0 4 (20)
commodation/Expenses: Roche; Research grant/Funding (institution): Novartis; Research grant/ Partial response 2 (28.6) 5 (22.7) 5 (25)
Funding (institution): MSD. L. Bengrine Lefevre: Advisory/Consultancy: AstraZeneca. M-A. Mouret- Stable disease 2 (28.6) 6 (27.3) 10 (50)
Reynier: Honoraria (institution): Pfizer; Honoraria (institution): Roche; Honoraria (institution): MSD; PD 3 (42.9) 11 (50.0) 1 (5)
Honoraria (institution): Lilly; Honoraria (institution): Novartis; Honoraria (institution): AstraZeneca;
Honoraria (institution): Myriad. B. Asselain: Honoraria (self): AstraZeneca; Honoraria (self): BMS; mPFS (mo, 95%CI) 5.1(3.2-) 5.1 (4.0-9.0) 9.4 (6.7-14.0) 0.055
Honoraria (self): Pierre Fabre; Honoraria (self): Servier. C. Gavoille: Speaker Bureau/Expert testimony, mOS (mo, 95%CI) 6.8 (3.12-) 14.2 (9.4-) 28.2 (11.9-) 0.018
Travel/Accommodation/Expenses: AstraZeneca; Speaker Bureau/Expert testimony, Research grant/ *Evaluable p (n¼49).
Funding (institution), Travel/Accommodation/Expenses: Tesaro; Travel/Accommodation/Expenses:
Mundipharma; Research grant/Funding (institution): Fujirebio. D. Spaeth: Honoraria (self): Astra-
Zeneca; Travel/Accommodation/Expenses: Pfizer. E. Colomba: Advisory/Consultancy, Travel/Accom- Conclusions: Higher benefit from ssq Pt after PARPi was observed in the PFI>12
modation/Expenses: Ipsen; Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/ subgroup. Benefit from ssq Pt after PARPi in the PFI 6-12 subgroup was similar to
Consultancy, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Accommoda- benefit from CT in the non-Pt subgroup. The role of ssq Pt after PARPi in the PFI 6-12
tion/Expenses: Sanofi; Advisory/Consultancy, Travel/Accommodation/Expenses: GSK. A. Patsouris: subgroup warrants further research.
Honoraria (institution): Lilly; Research grant/Funding (self), Travel/Accommodation/Expenses: Eisai;
Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Pfizer. M. Fabbro: Legal entity responsible for the study: The authors.
Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: GSK. C. Chakiba: Honoraria (self): Roche;
Honoraria (self): AstraZeneca; Travel/Accommodation/Expenses: Pfizer. P. Toussaint: Honoraria (self), Funding: Has not received any funding.
Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consul- Disclosure: A. Plaja Salarich: Travel/Accommodation/Expenses: Angelini; Travel/Accommodation/
tancy, Travel/Accommodation/Expenses: Tesaro; Honoraria (self), Travel/Accommodation/Expenses: Expenses: Roche. B. Pardo Burdalo: Speaker Bureau/Expert testimony, Travel/Accommodation/Ex-
Pfizer; Travel/Accommodation/Expenses: Novartis. H. Simon: Advisory/Consultancy, Travel/Accom- penses: Roche; Speaker Bureau/Expert testimony: AstraZeneca; Speaker Bureau/Expert testimony,
modation/Expenses: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Ac- Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: GSK. M. Gil-Martin:
commodation/Expenses: Roche; Advisory/Consultancy: Sandoz; Advisory/Consultancy, Travel/ Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Speaker Bureau/Expert
Accommodation/Expenses: AstraZeneca; Speaker Bureau/Expert testimony: Tesaro; Speaker Bureau/ testimony: AstraZeneca; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Phar-
Expert testimony, Travel/Accommodation/Expenses: Lilly; Travel/Accommodation/Expenses: Pfizer. maMar; Travel/Accommodation/Expenses: MSD. J.M. Piulats: Advisory/Consultancy: Clovis; Advi-
D. Berton: Advisory/Consultancy, board: AstraZeneca; Advisory/Consultancy, board: Tesaro; Travel/ sory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy,
Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: PharmaMar. D. Garbay: Travel/ Research grant/Funding (institution): MSD; Advisory/Consultancy, Research grant/Funding (institu-
Accommodation/Expenses, congress: Pfizer; Non-remunerated activity/ies: Lisa (L’Institut du Sein tion): BeiGene. C. Fina Planas: Travel/Accommodation/Expenses: Roche; Travel/Accommodation/
Bordeaux Aquiitaine). C. Garnier Tixidre: Honoraria (self), Advisory/Consultancy, Travel/Accommo- Expenses: MSD; Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Bristol-
dation/Expenses: Pfizer; Speaker Bureau/Expert testimony: AstraZeneca; Research grant/Funding Myers. M.P. Barretina Ginesta: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Ac-
(institution): Roche; Travel/Accommodation/Expenses: MSD. D. Coeffic: Honoraria (self), Advisory/ commodation/Expenses: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony,
Consultancy: Roche; Honoraria (self), Advisory/Consultancy: AstraZeneca. C. Lefeuvre-Plesse: Advi- Travel/Accommodation/Expenses: GSK; Advisory/Consultancy, Speaker Bureau/Expert testimony,
sory/Consultancy: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Roche; Speaker Bureau/Expert testimony, Travel/Accommoda-
Travel/Accommodation/Expenses: Novartis; Travel/Accommodation/Expenses: Pfizer; Travel/Ac- tion/Expenses: PharmaMar; Advisory/Consultancy, Speaker Bureau/Expert testimony: Clovis
commodation/Expenses: Pierre Fabre. All other authors have declared no conflicts of interest. Oncology. M. Romeo Marin: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Tesaro;
Travel/Accommodation/Expenses: Pfizer. All other authors have declared no conflicts of interest.
https://doi.org/10.1016/j.annonc.2020.08.962
https://doi.org/10.1016/j.annonc.2020.08.963

824P Real-world-data (RWD) on platinum (Pt) outcomes after PARP

inhibitors (PARPi) progression in high grade serous ovarian cancer 825P Olaparib maintenance therapy in routine clinical practice: Quality of
(HGSOC) patients (p) life interim results of the non-interventional C-PATROL study in
ovarian cancer patients in Germany
A. Plaja Salarich1, I. Teruel García1, B. Pardo Burdalo2, M. Gil-Martin3, J.M. Piulats4,
C. Fina Planas5, M.P. Barretina Ginesta5, A. Ferrando Diez1, L. Notario Rincon1, F. Marmé1, F. Hilpert2, M.K. Welslau3, J.P. Grabowski4, A. El-Balat5, A. Hartkopf6,
A. Pous Badia1, A. Gonzalez Valencia6, A. Esteve Gomez6, M. Romeo Marin1 R. Glowik7, J. Sehouli8
1 1
Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Ger- Gynecologic Oncology Department, UMM - Universitaetsklinikum Mannheim -
mans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Medizinische Fakultaet, Mannheim, Germany; 2Mammzentrum, Krankenhaus Jerusa-
Oncology (B-ARGO), Badalona, Spain; 2Medical Oncology Department, Catalan Insti- lem, Hamburg, Germany; 3Oncology Department, Klinikum Aschaffenburg, Aschaf-
tute of Oncology (ICO)-IDIBELL, L’Hospitalet, Barcelona, Spain; 3Medical Oncology fenburg, Germany; 4Department of Gynecology, Campus Virchow Clinic, Charité
Department, Institut Català d’Oncologia-IDIBELL, L’Hospitalet-Barcelona, Spain, Bar- Medical University Berlin, Berlin, Germany; 5Gynaekologisch-Onkologisches Krebs-
celona, Spain; 4Medical Oncology, Catalan Institute of Oncology, Barcelona, Spain; zentrum, Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute),
5
Medical Oncology Department, Catalan Institute of Oncology (ICO)-Girona, Girona Frankfurt am Main, Germany; 6Department of Womens Health, Uni-
Biomedical Research Institute (IDIBGI), Girona, Spain; 6Statistical Department, Catalan versitätsfrauenklinik Tübingen, Tubingen, Germany; 7Medical Affairs, AstraZeneca
Institute of Oncology (ICO)-Badalona, Badalona, Spain Germany, Wedel, Germany; 8Department of Gynecology and Center for Oncological
Surgery, Charité Medical University, Berlin, Germany
Background: PARPi maintenance after Pt-based chemotherapy (CT) significantly im-
proves progression-free survival (PFS) and PFS to subsequent (ssq) chemotherapy Background: The preservation of health-related quality of life (HRQoL) is a very
(PFS2) in relapsed HGSOC. However, crossed mechanisms of action and resistance important treatment goal in relapsed ovarian cancer (OC) patients during mainte-
nance treatment. Olaparib hard capsules were the first poly (ADP-ribose) polymerase

S622 Volume 31 - Issue S4 - 2020